Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study

Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism of the dihydropyrimidine dehydrogenase (<i>DPYD</i>) gene may reduce DPD function, the main enzyme responsible for the metabolism of fluoropyrimidines. This leads to drug accumulation and to an increas...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Paula Soria-Chacartegui, Gonzalo Villapalos-García, Luis A. López-Fernández, Marcos Navares-Gómez, Gina Mejía-Abril, Francisco Abad-Santos, Pablo Zubiaur
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2021-11-01
Serija:	Pharmaceutics
Teme:	dihydropyrimidine dehydrogenase (<i>DPYD</i>) capecitabine 5-fluorouracil polymorphism pharmacogenetics
Online dostop:	https://www.mdpi.com/1999-4923/13/12/2036
Oznake:	Označite Brez oznak, prvi označite!